- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07791719
Effects of Different PICC Catheterization Methods: A Multicenter Randomized Controlled Trial
25. August 2026 aktualisiert von: Zeyin Hu, Sun Yat-sen University
This study aims to compare the clinical effectiveness of three PICC (Peripherally Inserted Central Catheter) insertion methods: conventional non-tunneled PICC, one-needle tunneled PICC, and two-needle tunneled PICC.
This is a multicenter randomized controlled trial involving 11 hospitals in China, with a total of 801 patients scheduled to undergo PICC insertion for the first time.
Patients will be randomly assigned in a 1:1:1 ratio to the three groups.
The primary outcome is the incidence of post-insertion complications (including oozing, infection, thrombosis, catheter dislodgement, etc.) within 90 days.
Secondary outcomes include one-time puncture success rate, pain level (NRS), bleeding volume, catheterization time, and unplanned catheter removal rate.
The results will provide evidence for selecting the optimal PICC insertion method in clinical practice.
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Detaillierte Beschreibung
This study adopts a prospective, multicenter, three-arm, parallel-group randomized controlled design.
A total of 801 patients will be recruited from 11 hospitals and randomly assigned in a 1:1:1 ratio to the three groups.
The control group receives conventional non-tunneled PICC insertion.
Experimental group 1 receives one-needle tunneled insertion (the needle travels subcutaneously for 4 cm before entering the vessel).
Experimental group 2 receives two-needle tunneled insertion (with a 4 cm subcutaneous tunnel created using a tunneling tool).
All insertions are performed by certified PICC nurses with over 5 years of experience who have received standardized training.
The primary outcome is the overall incidence of catheter-related complications within 90 days post-insertion.
Secondary outcomes include one-time puncture success rate, NRS pain score, intraoperative bleeding volume, catheterization time, and unplanned catheter removal rate.
Outcome assessors and data analysts are blinded to group allocation.
The study has been approved by the Ethics Committee of Sun Yat-sen University Cancer Center (Approval No. B2026-467-01, dated August 10, 2026).
Studientyp
Interventionell
Einschreibung (Geschätzt)
801
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Zeyin Hu
- Telefonnummer: 86+15899954190
- E-Mail: huzy@sysucc.org.cn
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Jiasheng Huang
- Telefonnummer: 86+17602023464
- E-Mail: huangjs1@sysucc.org.cn
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Age 18 to 75 years
- Education level of primary school or above, with adequate reading, writing and --communication skills to independently complete the questionnaire
- First-time PICC insertion using a 4Fr single-lumen solo PICC catheter
- Able to attend follow-up visits at the same hospital for catheter maintenance after insertion
- Willing to participate in the study and sign the informed consent form and PICC insertion consent form
Exclusion Criteria:
- Coagulation dysfunction (INR > 1.5 or PLT < 25 × 10⁹/L)
- Use of anticoagulants (e.g., warfarin, heparin) within 3 days before catheterization
- Pregnant or lactating women
- BMI < 18.5 kg/m²
- Patients requiring lower extremity PICC insertion
- Known or suspected allergy to components of the PICC catheter
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Conventional Non-Tunneled PICC catheterization
Patients receive conventional non-tunneled PICC insertion.
The procedure involves ultrasound-guided vein puncture, guidewire insertion, local anesthesia and skin dilation, followed by sheath and catheter advancement.
The catheter exit site is at the puncture site.
|
Ultrasound-guided vein puncture, followed by guidewire insertion, local anesthesia, skin dilation, sheath advancement, and catheter delivery.
The catheter exit site is at the puncture site with no subcutaneous tunnel created.
|
|
Experimental: One-Needle Tunneled PICC catheterization
Patients receive one-needle tunneled PICC insertion.
The puncture needle travels subcutaneously for 4 cm before entering the vessel, creating a subcutaneous tunnel.
The skin puncture and catheter exit sites are the same.
This technique requires only one needle pass for both tunneling and vessel puncture.
|
The puncture needle travels subcutaneously for 4 cm before entering the vessel, creating a subcutaneous tunnel with a single needle pass.
The puncture site and catheter exit site are the same.
This technique combines tunneling and vessel puncture in one step.
|
|
Experimental: Two-Needle Tunneled PICC catheterization
Patients receive two-needle tunneled PICC insertion.
Ultrasound-guided vein puncture is performed first, followed by creation of a 4 cm subcutaneous tunnel using a tunneling tool.
The puncture site and catheter exit site are separate, with a subcutaneous tunnel connecting them.
|
A two-step procedure: first, ultrasound-guided vein puncture is performed; then, a separate subcutaneous tunnel of 4 cm is created using a tunneling tool.
The puncture site and catheter exit site are separate, connected by a subcutaneous tunnel.
The catheter is pulled through the tunnel from the exit site to the puncture site.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Incidence of Catheter-Related Complications Within 90 Days Post-catheterization
Zeitfenster: From catheterization to 90 days post-catheterization
|
The composite endpoint includes: oozing/exudation at the catheter exit site, mechanical phlebitis, catheter-related bloodstream infection, local or tunnel infection, catheter-related thrombosis, catheter dislodgement or migration, catheter occlusion, contact dermatitis, and catheter breakage or damage.
All complications are assessed from the day of insertion up to 90 days post-insertion.
|
From catheterization to 90 days post-catheterization
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
One-Time Puncture Success Rate
Zeitfenster: Day 1 During catheterization procedure
|
Proportion of patients in whom the first puncture successfully enters the vein and the guidewire is smoothly advanced.
|
Day 1 During catheterization procedure
|
|
Pain Intensity During Catheterization (NRS Score)
Zeitfenster: Day 1 Immediately after catheterization procedure
|
Pain level assessed using the Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain) immediately after catheterization.
|
Day 1 Immediately after catheterization procedure
|
|
Intraoperative Bleeding Volume
Zeitfenster: Day 1 From start to end of catheterization procedure
|
Total bleeding volume during catheterization, calculated by weighing gauze pads before and after the procedure (converted using whole blood specific gravity of 1.05 g/mL).
|
Day 1 From start to end of catheterization procedure
|
|
Catheterization Procedure Time
Zeitfenster: Day 1 During catheterization procedure
|
Time from the first skin puncture to the moment the catheter is delivered to the predetermined length.
|
Day 1 During catheterization procedure
|
|
Unplanned Catheter Removal Rate
Zeitfenster: From Day 1 catheterization to 90 days post-catheterization
|
Proportion of catheters removed prematurely due to complications (e.g., infection, thrombosis, dislodgement, occlusion) before the completion of treatment.
|
From Day 1 catheterization to 90 days post-catheterization
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
10. September 2026
Primärer Abschluss (Geschätzt)
30. Mai 2027
Studienabschluss (Geschätzt)
30. August 2027
Studienanmeldedaten
Zuerst eingereicht
25. August 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
25. August 2026
Zuerst gepostet (Tatsächlich)
28. August 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
28. August 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
25. August 2026
Zuletzt verifiziert
1. August 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- Different PICC catheterization
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
UNENTSCHIEDEN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .